SOX2 and PIK3CA Amplification as Prognostic Biomarkers in Advanced Lung Squamous Cell Carcinoma

Authors

• Fawzi Abu Rous, Henry Ford HealthFollow
• Michelle Weitz
• Radhika Gutta, Henry Ford HealthFollow
• Kayla Layng
• Jen Godden
• Stamatina Fragkogianni
• Shannon Carskadon, Henry Ford HealthFollow
• Geena Mody, Henry Ford HealthFollow
• Sudha Sadasivan, Henry Ford HealthFollow
• Bindu Potugari, Henry Ford HealthFollow
• Shirish Gadgeel, Henry Ford HealthFollow
• Nallasivam Palanisamy, Henry Ford HealthFollow

Recommended Citation

Abu Rous F, Weitz M, Gutta R, Layng K, Godden J, Fragkogianni S, Carskadon S, Mody G, Sadasivan S, Potugari B, Gadgeel S, Palanisamy N. SOX2 and PIK3CA Amplification as Prognostic Biomarkers in Advanced Lung Squamous Cell Carcinoma. J Thorac Oncol 2026; 21(7):S30-S31.

Document Type

Conference Proceeding

Publication Date

7-1-2026

Publication Title

J Thorac Oncol

Keywords

Oncology, Respiratory System

Abstract

Chromosome 3q amplification is a frequent genomic alteration in lung squamous cell carcinoma (LUSC), implicated in tumor initiation, progression, and immune evasion. We identified a minimal common region (MCR) spanning 25 genes with potential prognostic and predictive value. Given the strong correlation between MCR amplification and SOX2/PIK3CA amplification, we used these genes as practical surrogates for MCR status. We characterized genomic, immunologic, and clinical features of MCR-amplified tumors and their association with outcomes following immune checkpoint inhibitor (ICI)-based therapy.

Volume

21

Issue

7

First Page

S30

Last Page

S31